Clinical trial
Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With…
NCT00344513 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00344513 |
|---|---|
| Title | Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF) |
| Official title | Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Drug |
| Interventions | Beta-blockers including Carvedilol, ACE inhibitors |
| Enrollment | 50,000 |
| Start date | Dec 16, 2002 |
| Completion | Jun 30, 2005 |
| First posted | Jun 26, 2006 |
| Last update posted | Nov 24, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: